- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03449264
Development of Clinical and Biological Database (BCBInstitut)
Development of a Monocentric and Prospective Clinical and Biological Database in Digestive Cancers, Gynecological Cancers, Breast Cancers and Sarcomas
The BCB is a tool:
- for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials;
- to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations;
- to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes.
The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Implementation of a translational research project is part of the Cancer Plan 2014-2019 and its axis 5 "Advancing clinical and translational research in oncology", and more precisely Action 5.1.
The national health strategy launched by the Minister of Health and the Minister of Research will allow a better integration between research, innovation, medicine and care for the benefit of patients and society.
Moreover, knowledge of mechanisms involved in the phenomena of tumor invasion, metastatic dissemination, resistance to treatment and companion testing is crucial for the emergence of new biomarkers and therapeutic innovation.
However, the study of the earliest phases of tumorigenesis as well as of the advanced stages of the disease are currently limited by the low availability of blood and tissue samples combined with quality and reliable clinical data.
To meet these demands, the research must then integrate databases creation open to researchers and the ongoing evaluation of the impact of projects on the health of cancer patients.
Integrated research associated with quality biological research is the guarantee of medical progress.
The multidisciplinary structure around collections of biological resources will enable the various actors to harmonize not only the collection but also the sharing of their data with a view to making them available for medico-scientific projects at a regional and national dimension. The Clinical Biological Database (BCB) should be used to identify and characterize new molecular markers for better diagnosis and / or treatment. It should also permit to optimize the collection of all this information, their integration and their transversal exploitation by different research disciplines (epidemiological, fundamental, translational, clinical).
The BCB is a tool:
- for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials;
- to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations;
- to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes.
The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: david azria
- Numéro de téléphone: +33467613102
- E-mail: david.azria@icm.unicancer.fr
Lieux d'étude
-
-
-
Montpellier, France, 34298
- Recrutement
- Institut regional du Cancer - Val d Aurelle
-
Contact:
- BLEUSE Jean-pierre, MHD
-
Chercheur principal:
- AZRIA David, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age> at 18 years old,
- Patient with invasive or in situ tumor pathology (proven or suspected) any stage confounded,
Patient in ICM at diagnosis
- a digestive cancer (esophagus, stomach, pancreas, colon, rectum, anal canal) or
- gynecological cancer (ovary, endometrium, cervix) or
- breast cancer or
- sarcoma.
- Naïve patient of any treatment for the present cancer,
- Patient requiring treatment involving at least one (or more) tumor surgery (s)
- Patient who has accepted supplementary blood samples,
- Patient having given his informed, written and express consent.
Exclusion Criteria:
- Patient not affiliated to a social protection scheme,
- Patient whose regular follow-up is a priori impossible for psychological, familial, social or geographical reasons,
- Pregnant and / or nursing women,
- Subject under tutelage, curatorship or safeguard of justice,
- Patient in an emergency situation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Biological collection
samples of different natures:
In parallel to this biological collection, standardized clinical data will be entered into a database |
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Proportion of patients who consent to participate in the study
Délai: through study completion, an average of 1 year
|
the proportion of patients who consent to participate in the study among the screened patients
|
through study completion, an average of 1 year
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Quality of life assessment at baseline for all participants in the study
Délai: through study completion, an average of 1 year
|
Questionnaire assessment to measure the quality of life at baseline
|
through study completion, an average of 1 year
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: jean pierre Bleuse, Institut Regional du Cancer de Montpellier
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ICM-URC2017/37
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur biological collection
-
GlaxoSmithKlineComplétéInfections, PapillomavirusTaïwan, Thaïlande, Brésil
-
GlaxoSmithKlineComplétéRougeole | Rubéole | Oreillons | VaricelleInde
-
GlaxoSmithKlineComplétéInfections, PapillomavirusÉtats-Unis, Canada
-
GlaxoSmithKlineComplétéHépatite B | Tétanos | Diphtérie | Coqueluche acellulaire | Poliomyélite | Haemophilus influenzae de type bFinlande
-
Tianjin Medical University Cancer Institute and...RecrutementCancer de l'œsophageChine
-
GlaxoSmithKlineComplétéRougeole | Rubéole | Oreillons | Vaccin rougeole-oreillons-rubéoleÉtats-Unis, Porto Rico
-
GlaxoSmithKlineThe PATH Malaria Vaccine Initiative (MVI)Complété
-
Shanghai Institute Of Biological ProductsComplété
-
Jiangsu Province Centers for Disease Control and...ComplétéEffet indésirable et immunogénicité du vaccinChine